Stem Cell Pioneer Receives 2003 Frank Annunzio Award
MADISON, WI - James Thomson, the Wisconsin scientist who was the first to isolate and culture human embryonic stem cells five years ago, has been named the recipient of the 2003 Frank Annunzio Award from the Christopher Columbus Fellowship Foundation, an independent federal government agency. Annunzio Awards are presented annually to living Americans for improving the world through ingen...Meyerhoeffer Chalazion Curette
Description:3.5 mm cup. Straight 31 mm shaft with flat handle and polished finish. Overall length: 4.9 inches....DK Meyerhoefer Chalazion Curette
Description:2.0 mm cup , straight shaft, Flat handle, length 125.0 mm....Lambert Chalazion Forceps - Large
Description:Round solid lower plate. Open upper plate with inside diameter 15 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
NEW YORK--(BUSINESS WIRE)--Jul 6, 2007 - ZIOPHARM Oncology, Inc.(NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, ChiefExecutive Officer, will present at the C.E. Unterberg, TowbinEmerging Growth Opportunities Conference on Thursday, July 12, 2007at 2:30 p.m. ET at the Mandarin Oriental Hotel, New York. Dr. Lewiswill provide an overview of the Company and an update on itsclinical deve...Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARMOncology, Inc. (NASDAQ: ZIOP) announces that positive interim datafrom an ongoing phase II trial of ZIO-201 (isophosphoramide mustard- IPM) to treat advanced sarcoma patients was presented at theEuropean Society of Medical Oncology (ESMO) meeting held July 5-8,2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/IIStudy of...ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP) announced today the presentation of preclinicaldata strongly supportive of the development of an oral form ofZIO-101. Specifically, ZIO-101 demonstrates very highbioavailability when administered orally; in addition it evidencesanti-angiogenic activity that is particularly well suited to oraladministration. T...ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP) announced today the presentation of preclinicaldata for an orally active form of ZIO-201 (isophosphoramide mustard- IPM) at the American Association of Cancer Research meeting beingheld in Los Angeles. Data presented demonstrated oral availabilityof ZIO-201 and activity in a variety of cancer models, including...